Summary It has recently been found by various authors that despite a normal serum concentration of oestradiol (E2), the percentage of non-protein-bound or free E2 is abnormally high in breast cancer patients. Since it is the free E2 which is considered to be biologically active, confirmation of this finding would matched controls. Our findings do not support the hypothesis that the pathogenesis of breast cancer is related to an elevated free fraction of the total E2 concentration in blood. However, the free E2 concentration, as calculated from the total E2 concentration and the free E2 fraction is shown to be abnormally high in postmenopausal breast cancer patients as a consequence of their elevated total serum E2 concentration.
Endocrine factors are thought to play a role in the pathogenesis of cancer of the breast and various other hormone responsive organs in man. As blood levels of hormones are considered to be representative of their direct influence on target cells, more sensitive and direct immunological assay methods applied to serum or plasma have largely replaced the determination of urinary hormone metabolites. Oestrogens, progestins, weak androgens and lactogenic hormones like prolactin have been the main topic of the endocrine investigations in breast cancer. The results of all the research performed to date are conflicting. No unequivocal hormonal abnormality could be discovered in patients with breast cancer or in women at risk. It was therefore most exciting when Siiteri et al. (1981) , published data on the elevated non-protein bound oestradiol (free E2) fraction in the serum of breast cancer patients. This finding appeared to be most relevant to the alleged promotor function of E2, despite the existence of normal serum concentrations of total E2, since it is the free E2 fraction which is supposed to be biologically active.
We have measured both the free E2 fraction as a percentage of the total E2 concentration, and the actual E2 concentration in the blood from women at risk of breast cancer, breast cancer patients and matched controls. Our findings do not support the hypothesis that the pathogenesis of breast cancer is related to an elevated free fraction of the total E2 concentration in blood. However, the free E2 concentration, as calculated from the total E2 concentration and the free E2 fraction is shown to be abnormally high in postmenopausal breast cancer patients as a consequence of their elevated total serum E2 concentration.
Subjects and methods

Subjects
Serum samples were obtained from 38 postmenopausal breast cancer patients and a control group of 67 women admitted for malignant lymphoma (n = 21), melanoma (n = 5), cancer of the lung (n = 21) or large bowel (n = 20). The two groups were matched for age, parity and Quietelet index (in Kg m 2) as shown in Table I . All women were clinically judged to have normal thyroid function.
Heparinized plasma was collected by continuous venous sampling from 68 premenopausal women belonging to one of the following 4 groups: 18 women at a high familial risk for breast cancer, i.e. mother and at least one sister having breast cancer (group R), 17 women curatively treated for early (TINOMO) (Bruning et al., 1984) .
All samples had been stored at -20°C (maximum 3 years) and had not been thawed before use.
Analytical methods Total E2 concentration was measured by a conventional radioimmunoassay. Serum extraction with ether was followed by Sephadex LH-20 chromatographic separation. A highly specific antiserum raised against E2-6-0-carboxy-methyloxime-bovine serum albumin was used (Bulbrook et al., 1978) . Progesterone was measured with a commercial radioimmunoassay-kit (Farmos, Turku, Finland).
The percentage of free E2 was measured by centrifugal ultrafiltration dialysis of undiluted serum or plasma at +37°C (Durnin & Womersley, 1974) .
Results
As can be seen from Table III The data in Table IV indicate that no significant differences between groups were found in the heparinized plasma samples obtained from the premenopausal women of groups R, B, C and N.
A very good correlation between SHBG and free E2 percentage was observed (P<0.0001). Analysis of co-variance demonstrated that the regression lines of log free E2 percentage vs log SHBG shown in Figure 1 were identical for groups R, B, C and N. Figure 2 illustrates that the regression line for the postmenopausal breast cancer patient serum samples was identical to that for the control serum samples, and ran nearly parallel to the line derived from the premenopausal plasma samples, though somewhat lower. This was apparently due to a somewhat lower free E2 percentage in the cancer patient sera (P <0.03), SHBG being similar in serum and in heparinized plasma samples. In order to exclude the possibility that the latter difference could result from a difference between serum and heparinized plasma we have determined the free E2 percentage in heparinized plasma and serum collected simultaneously from 24 healthy individuals. Figure  3 shows an excellent correlation between the free E2 values in plasma and in serum.
The free E2 concentration was calculated from free E2 as a percentage of the total E2 concentration. No finding is consistent with data obtained by Moore et al. (1982) .
Although Reed et al. (1983) used an equilibrium dialysis technique, Moore et al. (1982) and Siiteri et al. (1981) used the same centrifugal ultrafiltration dialysis method as we did to determine the free E2 fraction . There were no differences in the [3H]-DHT binding capacity of SHBG or albumin concentrations between our groups which could explain the discrepancies between our data and the free E2 results obtained by Moore et al. and Reed et We could confirm the strong inverse correlation between SHBG and free E2 percentage (not free E2 concentration) as was demonstrated before (Siiteri et al., 1981 , Moore et al., 1982 , Reed et al., 1983 .
However, we have no indication that, as Moore et al. (1982) concluded, for a given SHBG concentration less E2 would be bound in breast cancer patients than in the control population since the regression lines for log free E2 percentage vs log SHBG are identical for our breast cancer groups and their respective matched control groups.
A small, but statistically significant difference in free E2 percentage was observed between the premenopausal plasma samples and the postmenopausal serum samples. This difference could not be ascribed to the difference between serum and heparinized plasma itself as shown in (Kopelman et al., 1980) and in postmenopausal women with endometrial cancer . However, we could not find significant correlations between free E2 percentage and age, body weight or body fat mass respectively. We conclude that some other factor(s), possibly related to the menopausal status, may be involved. If free E2 in blood is to be regarded as important since it represents the biologically active fraction of the total E2 concentration, then the free E2 concentratioh, not the mere free E2 fraction expressed as a percentage of the total E2 concentration should be considered. Our data do not support a role for a measurable elevated blood free E2 fraction. However, we did find an elevated total E2 concentration in the serum of postmenopausal breast cancer patients from which a significantly elevated free E2 concentration could be calculated. This increase in 'E2 -availability' may be meaningful in the modulation of breast cancer. The discrepancy between our findings and those of Moore et al. (1982) , using the same method to measure the free E2 fraction, might be explained by differences in the serum concentrations of free fatty acids which are inversely related to the free E2 fraction (Bruning & Bonfrer, unpublished observations).
Geographical differences in sex steroid binding to serum proteins may exist as a result of life style or genetic factors.
